Reclassification of risk of malignancy with Percepta Genomic Sequencing Classifier following nondiagnostic bronchoscopy

• Published in: Respiratory medicine Vol. 204; p. 106990
• Main Authors: Raval, Abhijit A., Benn, Bryan S., Benzaquen, Sadia, Maouelainin, Nina, Johnson, Marla, Huang, Jing, Lofaro, Lori R., Ansari, Adeeb, Geurink, Corey, Kennedy, Giulia C., Bulman, William A., Kurman, Jonathan S.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.11.2022
• Subjects: Biomarker; Bronchoscopy; Genomic classifier; Lung cancer; Lung nodules; Bronchoscopy; Genomic classifier; Biomarker; Lung nodules; Lung cancer
• ISSN: 0954-6111; 1532-3064
• DOI: 10.1016/j.rmed.2022.106990

Bronchoscopic sampling of pulmonary lesions suspicious for lung cancer is frequently nondiagnostic. A genomic sequencing classifier utilizing bronchial brushings obtained at the time of the bronchoscopy has been shown to provide an accurate reclassification of the risk of malignancy (ROM) based on pre-procedure risk. Our objectives for this study were to determine the frequency with which the classifier up- or down-classifies risk in regular clinical practice and to model the potential clinical utility of that reclassification. This observational study retrospectively assessed data from four clinical sites that regularly use the genomic classifier in the bronchoscopic evaluation of indeterminate lesions. Demographics and pre-bronchoscopy ROM were recorded. The frequency of up- and down-classification was calculated. Modeling based on reclassification rates and the performance characteristics of the classifier was performed to demonstrate the potential clinical utility of the result. 86 patients who underwent classifier testing following a nondiagnostic bronchoscopy were included. 45% of patients with high ROM prior to bronchoscopy were reclassified very high-risk. 38% of patients with intermediate ROM were up-or down-classified. 56% of patients with low ROM were reclassified to very low-risk. Overall, 42% of patients had a change in classification. 35% of the study cohort could potentially have avoided additional unnecessary procedures with subsequent guideline-adherent management. The classifier can guide decision-making following a nondiagnostic bronchoscopy, reclassifying risk in a significant percentage of cases. Use of the classifier should allow more patients with early-stage cancer to proceed directly to curative therapy while helping more patients with benign disease avoid further unnecessary procedures. •Percepta GSC can reclassify malignancy risk after nondiagnostic bronchoscopy.•Data from four sites show that 42% of patients had a change in risk classification.•35% of patients could potentially have avoided additional unnecessary procedures.